Spoken Alpha
FENNEC PHARMACEUTICALS INC.
Fennec Pharmaceuticals develops and commercializes PEDMARK®, an FDA- and European Commission-approved injectable treatment that reduces hearing loss from cisplatin chemotherapy in pediatric cancer patients.
FENNEC PHARMACEUTICALS INC is a Healthcare company operating in Biotechnology with a $373.1M market cap.
FENC beat consensus EPS by 1.0% in Q2 FY2026, reported Aug 10, 2026.
12 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for FENC.
$ curl https://api.spokenalpha.com/v1/companies/FENCFAQ
Spoken Alpha indexes FENC's earnings call transcripts at https://spokenalpha.com/companies/FENC. Each call links to attributed speakers and parsed analyst Q&A. FENNEC PHARMACEUTICALS INC.'s own investor relations page is at https://investors.fennecpharma.com/.
FENNEC PHARMACEUTICALS INC. (FENC) held its most recent earnings call on 2026-05-14, covering fiscal Q1 2026.
FENNEC PHARMACEUTICALS INC. (FENC) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-10 | $0.05 | $0.01 | +100.0% | $17.9M | — | — | EODHD |
| Q1 FY2026 | 2026-03-31 | $0.01 | $0.03 | -70.2% | $15.1M | — | — | EODHD |
| Q4 FY2025 | 2026-03-23 | $-0.10 | $0.04 | -100.0% | $13.8M | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-0.02 | $-0.02 | 0.0% | $12.5M | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-0.11 | $-0.03 | -100.0% | $9.7M | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-0.04 | $-0.08 | +50.0% | $8.8M | — | — | EODHD |
| Q4 FY2024 | 2025-03-09 | $-0.06 | $-0.13 | +53.8% | $7.9M | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.21 | $-0.08 | -100.0% | $7.0M | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-0.20 | $0.02 | -100.0% | $7.3M | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $0.41 | $-0.04 | +100.0% | $25.4M | — | — | EODHD |
| Q4 FY2023 | 2024-03-20 | $-0.10 | $-0.02 | -100.0% | $9.7M | — | — | EODHD |
| Q3 FY2023 | 2023-11-05 | $-0.07 | $-0.13 | +46.2% | $6.5M | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-0.21 | $-0.16 | -31.3% | $3.3M | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.23 | $-0.19 | -21.1% | $1.7M | — | — | EODHD |
| Q4 FY2022 | 2023-03-28 | $-0.26 | $-0.26 | 0.0% | $1.5M | — | — | EODHD |
| Q3 FY2022 | 2022-11-10 | $-0.31 | $-0.19 | -63.2% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-11 | $-0.19 | $-0.13 | -46.2% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-0.14 | $-0.14 | 0.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-02-27 | $-0.18 | $0.75 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-09 | $-0.16 | $-0.14 | -14.3% | $0 | — | — | EODHD |
Source: EODHD. FENC reported actuals as published; sparse fields render as —.